{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T17:58:17Z","timestamp":1793642297929,"version":"4.5.1"},"reference-count":130,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T00:00:00Z","timestamp":1755475200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T00:00:00Z","timestamp":1755475200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000925","name":"Department of Health | National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1138448"],"award-info":[{"award-number":["1138448"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"Department of Health | National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1196951"],"award-info":[{"award-number":["1196951"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001030","name":"National Heart Foundation of Australia","doi-asserted-by":"publisher","award":["101857"],"award-info":[{"award-number":["101857"]}],"id":[{"id":"10.13039\/501100001030","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Adenosine receptors (ARs: A\n                    <jats:sub>1<\/jats:sub>\n                    AR, A\n                    <jats:sub>2A<\/jats:sub>\n                    AR, A\n                    <jats:sub>2B<\/jats:sub>\n                    AR, and A\n                    <jats:sub>3<\/jats:sub>\n                    AR) are crucial therapeutic targets; however, developing selective, efficacious drugs for them remains a significant challenge. Here, we present high-resolution cryo-electron microscopy (cryo-EM) structures of the human A\n                    <jats:sub>3<\/jats:sub>\n                    AR in three distinct functional states: bound to the endogenous agonist adenosine, the clinically relevant agonist Piclidenoson, and the covalent antagonist LUF7602. These structures, complemented by mutagenesis and pharmacological studies, reveal an A\n                    <jats:sub>3<\/jats:sub>\n                    AR activation mechanism that involves an extensive hydrogen bond network from the extracellular surface down to the orthosteric binding site. In addition, we identify a cryptic pocket that accommodates the N\n                    <jats:sup>6<\/jats:sup>\n                    -iodobenzyl group of Piclidenoson through a ligand-dependent conformational change of M174\n                    <jats:sup>5.35<\/jats:sup>\n                    . Our comprehensive structural and functional characterisation of A\n                    <jats:sub>3<\/jats:sub>\n                    AR advances our understanding of adenosine receptor pharmacology and establishes a foundation for developing more selective therapeutics for various disorders, including inflammatory diseases, cancer, and glaucoma.\n                  <\/jats:p>","DOI":"10.1038\/s41467-025-62872-x","type":"journal-article","created":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T11:25:27Z","timestamp":1755516327000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Molecular basis of ligand binding and receptor activation at the human A3 adenosine receptor"],"prefix":"10.1038","volume":"16","author":[{"given":"Liudi","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6979-1427","authenticated-orcid":false,"given":"Jesse I.","family":"Mobbs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2806-608X","authenticated-orcid":false,"given":"Felix M.","family":"Bennetts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5230-2973","authenticated-orcid":false,"given":"Hariprasad","family":"Venugopal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anh T. N.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4442-3294","authenticated-orcid":false,"given":"Arthur","family":"Christopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3662-8177","authenticated-orcid":false,"given":"Daan","family":"van der Es","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1381-8464","authenticated-orcid":false,"given":"Laura H.","family":"Heitman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4412-1707","authenticated-orcid":false,"given":"Lauren T.","family":"May","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4146-965X","authenticated-orcid":false,"given":"Alisa","family":"Glukhova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0325-2524","authenticated-orcid":false,"given":"David M.","family":"Thal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,18]]},"reference":[{"key":"62872_CR1","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/nrd1983","volume":"5","author":"KA Jacobson","year":"2006","unstructured":"Jacobson, K. A. & Gao, Z. G. Adenosine receptors as therapeutic targets. Nat. Rev. Drug Discov. 5, 247\u2013264 (2006).","journal-title":"Nat. Rev. Drug Discov."},{"key":"62872_CR2","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1124\/pharmrev.121.000445","volume":"74","author":"AP IJzerman","year":"2022","unstructured":"IJzerman, A. P., Jacobson, K. A., M\u00fcller, C. E., Cronstein, B. N. & Cunha, R. A. International union of basic and clinical pharmacology. CXII: adenosine receptors: a further update. Pharm. Rev. 74, 340\u2013372 (2022).","journal-title":"Pharm. Rev."},{"key":"62872_CR3","doi-asserted-by":"publisher","first-page":"124","DOI":"10.3389\/fncel.2019.00124","volume":"13","author":"KA Jacobson","year":"2019","unstructured":"Jacobson, K. A., Tosh, D. K., Jain, S. & Gao, Z. G. Historical and current adenosine receptor agonists in preclinical and clinical development. Front. Cell Neurosci. 13, 124 (2019).","journal-title":"Front. Cell Neurosci."},{"key":"62872_CR4","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1124\/pr.113.008540","volume":"67","author":"PA Borea","year":"2015","unstructured":"Borea, P. A. et al. The A3 adenosine receptor: history and perspectives. Pharm. Rev. 67, 74\u2013102 (2015).","journal-title":"Pharm. Rev."},{"key":"62872_CR5","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.drudis.2011.10.007","volume":"17","author":"P Fishman","year":"2012","unstructured":"Fishman, P., Bar-Yehuda, S., Liang, B. T. & Jacobson, K. A. Pharmacological and therapeutic effects of A3 adenosine receptor agonists. Drug Discov. Today 17, 359\u2013366 (2012).","journal-title":"Drug Discov. Today"},{"key":"62872_CR6","doi-asserted-by":"publisher","first-page":"4472","DOI":"10.1158\/1078-0432.CCR-03-0651","volume":"10","author":"L Madi","year":"2004","unstructured":"Madi, L. et al. The A3 adenosine receptor is highly expressed in tumor versus normal cells: potential target for tumor growth inhibition. Clin. Cancer Res. 10, 4472\u20134479 (2004).","journal-title":"Clin. Cancer Res."},{"key":"62872_CR7","doi-asserted-by":"publisher","first-page":"5895","DOI":"10.1158\/1078-0432.CCR-1134-03","volume":"10","author":"S Gessi","year":"2004","unstructured":"Gessi, S. et al. Elevated expression of A3 adenosine receptors in human colorectal cancer is reflected in peripheral blood cells. Clin. Cancer Res. 10, 5895\u20135901 (2004).","journal-title":"Clin. Cancer Res."},{"key":"62872_CR8","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1164\/rccm.201006-0980OC","volume":"183","author":"K Varani","year":"2011","unstructured":"Varani, K. et al. A3 receptors are overexpressed in pleura from patients with mesothelioma and reduce cell growth via Akt\/nuclear factor-\u03baB pathway. Am. J. Respir. Crit. Care Med. 183, 522\u2013530 (2011).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"62872_CR9","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1016\/j.bbamem.2010.09.020","volume":"1808","author":"S Gessi","year":"2011","unstructured":"Gessi, S., Merighi, S., Sacchetto, V., Simioni, C. & Borea, P. A. Adenosine receptors and cancer. Biochim. Biophys. Acta 1808, 1400\u20131412 (2011).","journal-title":"Biochim. Biophys. Acta"},{"key":"62872_CR10","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1593\/neo.05334","volume":"7","author":"S Merighi","year":"2005","unstructured":"Merighi, S. et al. A3 adenosine receptors modulate hypoxia-inducible factor-1alpha expression in human A375 melanoma cells. Neoplasia 7, 894\u2013903 (2005).","journal-title":"Neoplasia"},{"key":"62872_CR11","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1002\/jcp.20994","volume":"211","author":"S Gessi","year":"2007","unstructured":"Gessi, S. et al. Adenosine receptors in colon carcinoma tissues and colon tumoral cell lines: focus on the A(3) adenosine subtype. J. Cell Physiol. 211, 826\u2013836 (2007).","journal-title":"J. Cell Physiol."},{"key":"62872_CR12","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.abb.2013.02.007","volume":"533","author":"M Sakowicz-Burkiewicz","year":"2013","unstructured":"Sakowicz-Burkiewicz, M. et al. Differential effect of adenosine receptors on growth of human colon cancer HCT 116 and HT-29 cell lines. Arch. Biochem. Biophys. 533, 47\u201354 (2013).","journal-title":"Arch. Biochem. Biophys."},{"key":"62872_CR13","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1002\/1097-4652(200101)186:1<19::AID-JCP1011>3.0.CO;2-3","volume":"186","author":"G Ohana","year":"2001","unstructured":"Ohana, G., Bar-Yehuda, S., Barer, F. & Fishman, P. Differential effect of adenosine on tumor and normal cell growth: focus on the A3 adenosine receptor. J. Cell Physiol. 186, 19\u201323 (2001).","journal-title":"J. Cell Physiol."},{"key":"62872_CR14","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1593\/neo.101628","volume":"13","author":"S Morello","year":"2011","unstructured":"Morello, S. et al. NK1.1 cells and CD8 T cells mediate the antitumor activity of Cl-IB-MECA in a mouse melanoma model. Neoplasia 13, 365\u2013373 (2011).","journal-title":"Neoplasia"},{"key":"62872_CR15","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1593\/neo.04364","volume":"7","author":"S Bar-Yehuda","year":"2005","unstructured":"Bar-Yehuda, S. et al. CF101, an agonist to the A3 adenosine receptor, enhances the chemotherapeutic effect of 5-fluorouracil in a colon carcinoma murine model. Neoplasia 7, 85\u201390 (2005).","journal-title":"Neoplasia"},{"key":"62872_CR16","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1111\/jdv.19811","volume":"38","author":"KA Papp","year":"2024","unstructured":"Papp, K. A. et al. Efficacy and safety of piclidenoson in plaque psoriasis: Results from a randomized phase 3 clinical trial (COMFORT-1). J. Eur. Acad. Dermatol Venereol. 38, 1112\u20131120 (2024).","journal-title":"J. Eur. Acad. Dermatol Venereol."},{"key":"62872_CR17","doi-asserted-by":"crossref","unstructured":"Fishman, P. Drugs targeting the A3 adenosine receptor: human clinical study data. Molecules 27, 3680 (2022).","DOI":"10.3390\/molecules27123680"},{"key":"62872_CR18","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/j.ophtha.2009.11.029","volume":"117","author":"I Avni","year":"2010","unstructured":"Avni, I. et al. Treatment of dry eye syndrome with orally administered CF101: data from a phase 2 clinical trial. Ophthalmology 117, 1287\u20131293 (2010).","journal-title":"Ophthalmology"},{"key":"62872_CR19","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1634\/theoncologist.2012-0211","volume":"18","author":"SM Stemmer","year":"2013","unstructured":"Stemmer, S. M. et al. CF102 for the treatment of hepatocellular carcinoma: a phase I\/II, open-label, dose-escalation study. Oncologist 18, 25\u201326 (2013).","journal-title":"Oncologist"},{"key":"62872_CR20","doi-asserted-by":"crossref","unstructured":"Stemmer, S. M. et al. Namodenoson in advanced hepatocellular carcinoma and Child\u2013Pugh B cirrhosis: randomized placebo-controlled clinical trial. Cancers 13, 187 (2021).","DOI":"10.3390\/cancers13020187"},{"key":"62872_CR21","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1111\/apt.16664","volume":"54","author":"R Safadi","year":"2021","unstructured":"Safadi, R. et al. Randomised clinical trial: a phase 2 double-blind study of namodenoson in non-alcoholic fatty liver disease and steatohepatitis. Aliment Pharm. Ther. 54, 1405\u20131415 (2021).","journal-title":"Aliment Pharm. Ther."},{"key":"62872_CR22","first-page":"41","volume":"35","author":"MH Silverman","year":"2008","unstructured":"Silverman, M. H. et al. Clinical evidence for utilization of the A3 adenosine receptor as a target to treat rheumatoid arthritis: data from a phase II clinical trial. J. Rheumatol. 35, 41\u201348 (2008).","journal-title":"J. Rheumatol."},{"key":"62872_CR23","doi-asserted-by":"publisher","first-page":"947","DOI":"10.3389\/fphar.2017.00947","volume":"8","author":"ZG Gao","year":"2017","unstructured":"Gao, Z. G. & Jacobson, K. A. Purinergic signaling in mast cell degranulation and asthma. Front. Pharm. 8, 947 (2017).","journal-title":"Front. Pharm."},{"key":"62872_CR24","doi-asserted-by":"publisher","first-page":"3775","DOI":"10.1016\/j.bmcl.2004.04.099","volume":"14","author":"T Okamura","year":"2004","unstructured":"Okamura, T. et al. Structure-activity relationships of adenosine A3 receptor ligands: new potential therapy for the treatment of glaucoma. Bioorg. Med. Chem. Lett. 14, 3775\u20133779 (2004).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"62872_CR25","doi-asserted-by":"publisher","first-page":"417","DOI":"10.2174\/1389557510101040417","volume":"1","author":"CE M\u00fcller","year":"2001","unstructured":"M\u00fcller, C. E. A(3) adenosine receptor antagonists. Mini Rev. Med Chem. 1, 417\u2013427 (2001).","journal-title":"Mini Rev. Med Chem."},{"key":"62872_CR26","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1167\/tvst.11.2.30","volume":"11","author":"Y Kim","year":"2022","unstructured":"Kim, Y. et al. HL3501, a novel selective A3 adenosine receptor antagonist, lowers intraocular pressure (IOP) in animal glaucoma models. Transl. Vis. Sci. Technol. 11, 30 (2022).","journal-title":"Transl. Vis. Sci. Technol."},{"key":"62872_CR27","doi-asserted-by":"publisher","first-page":"898","DOI":"10.3389\/fphar.2017.00898","volume":"8","author":"B Carpenter","year":"2017","unstructured":"Carpenter, B. & Lebon, G. Human adenosine A(2A) receptor: molecular mechanism of ligand binding and activation. Front Pharm. 8, 898 (2017).","journal-title":"Front Pharm."},{"key":"62872_CR28","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1126\/science.1164772","volume":"322","author":"VP Jaakola","year":"2008","unstructured":"Jaakola, V. P. et al. The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist. Science 322, 1211\u20131217 (2008).","journal-title":"Science"},{"key":"62872_CR29","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1126\/science.1202793","volume":"332","author":"F Xu","year":"2011","unstructured":"Xu, F. et al. Structure of an agonist-bound human A2A adenosine receptor. Science 332, 322\u2013327 (2011).","journal-title":"Science"},{"key":"62872_CR30","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/nature10136","volume":"474","author":"G Lebon","year":"2011","unstructured":"Lebon, G. et al. Agonist-bound adenosine A2A receptor structures reveal common features of GPCR activation. Nature 474, 521\u2013525 (2011).","journal-title":"Nature"},{"key":"62872_CR31","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/nature18966","volume":"536","author":"B Carpenter","year":"2016","unstructured":"Carpenter, B., Nehm\u00e9, R., Warne, T., Leslie, A. G. & Tate, C. G. Structure of the adenosine A(2A) receptor bound to an engineered G protein. Nature 536, 104\u2013107 (2016).","journal-title":"Nature"},{"key":"62872_CR32","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1016\/j.cell.2017.01.042","volume":"168","author":"A Glukhova","year":"2017","unstructured":"Glukhova, A. et al. Structure of the adenosine A(1) receptor reveals the basis for subtype selectivity. Cell 168, 867\u2013877.e813 (2017).","journal-title":"Cell"},{"key":"62872_CR33","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1016\/j.str.2017.06.012","volume":"25","author":"RKY Cheng","year":"2017","unstructured":"Cheng, R. K. Y. et al. Structures of human A(1) and A(2A) adenosine receptors with xanthines reveal determinants of selectivity. Structure 25, 1275\u20131285.e1274 (2017).","journal-title":"Structure"},{"key":"62872_CR34","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/s41586-018-0236-6","volume":"558","author":"CJ Draper-Joyce","year":"2018","unstructured":"Draper-Joyce, C. J. et al. Structure of the adenosine-bound human adenosine A(1) receptor-G(i) complex. Nature 558, 559\u2013563 (2018).","journal-title":"Nature"},{"key":"62872_CR35","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.add3709","volume":"8","author":"Y Chen","year":"2022","unstructured":"Chen, Y. et al. Cryo-EM structure of the human adenosine A(2B) receptor-G(s) signaling complex. Sci. Adv. 8, eadd3709 (2022).","journal-title":"Sci. Adv."},{"key":"62872_CR36","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1038\/s41586-021-03897-2","volume":"597","author":"CJ Draper-Joyce","year":"2021","unstructured":"Draper-Joyce, C. J. et al. Positive allosteric mechanisms of adenosine A(1) receptor-mediated analgesia. Nature 597, 571\u2013576 (2021).","journal-title":"Nature"},{"key":"62872_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-47207-6","volume":"15","author":"H Cai","year":"2024","unstructured":"Cai, H. et al. Cryo-EM structures of adenosine receptor A(3)AR bound to selective agonists. Nat. Commun. 15, 3252 (2024).","journal-title":"Nat. Commun."},{"key":"62872_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-53473-1","volume":"15","author":"HS Oshima","year":"2024","unstructured":"Oshima, H. S. et al. Structural insights into the agonist selectivity of the adenosine A(3) receptor. Nat. Commun. 15, 9294 (2024).","journal-title":"Nat. Commun."},{"key":"62872_CR39","doi-asserted-by":"crossref","unstructured":"Tsutsumi, N. et al. Structure of human Frizzled5 by fiducial-assisted cryo-EM supports a heterodimeric mechanism of canonical Wnt signaling. Elife 9, e58464 (2020).","DOI":"10.7554\/eLife.58464"},{"key":"62872_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15363-0","volume":"11","author":"S Mukherjee","year":"2020","unstructured":"Mukherjee, S. et al. Synthetic antibodies against BRIL as universal fiducial marks for single-particle cryoEM structure determination of membrane proteins. Nat. Commun. 11, 1598 (2020).","journal-title":"Nat. Commun."},{"key":"62872_CR41","doi-asserted-by":"publisher","first-page":"3539","DOI":"10.1021\/acs.jmedchem.8b02026","volume":"62","author":"X Yang","year":"2019","unstructured":"Yang, X. et al. Development of covalent ligands for G protein-coupled receptors: a case for the human adenosine A(3) receptor. J. Med. Chem. 62, 3539\u20133552 (2019).","journal-title":"J. Med. Chem."},{"key":"62872_CR42","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1002\/jcc.24673","volume":"38","author":"Y Kajiwara","year":"2017","unstructured":"Kajiwara, Y., Yasuda, S., Takamuku, Y., Murata, T. & Kinoshita, M. Identification of thermostabilizing mutations for a membrane protein whose three-dimensional structure is unknown. J. Comput. Chem. 38, 211\u2013223 (2017).","journal-title":"J. Comput. Chem."},{"key":"62872_CR43","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1038\/s41589-018-0152-y","volume":"14","author":"R Suno","year":"2018","unstructured":"Suno, R. et al. Structural insights into the subtype-selective antagonist binding to the M(2) muscarinic receptor. Nat. Chem. Biol. 14, 1150\u20131158 (2018).","journal-title":"Nat. Chem. Biol."},{"key":"62872_CR44","doi-asserted-by":"publisher","first-page":"26001","DOI":"10.1073\/pnas.1914446116","volume":"116","author":"Z Vuckovic","year":"2019","unstructured":"Vuckovic, Z. et al. Crystal structure of the M(5) muscarinic acetylcholine receptor. Proc. Natl. Acad. Sci. USA 116, 26001\u201326007 (2019).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"62872_CR45","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.sbi.2018.03.002","volume":"51","author":"DM Thal","year":"2018","unstructured":"Thal, D. M. et al. Recent advances in the determination of G protein-coupled receptor structures. Curr. Opin. Struct. Biol. 51, 28\u201334 (2018).","journal-title":"Curr. Opin. Struct. Biol."},{"key":"62872_CR46","doi-asserted-by":"crossref","unstructured":"Ballesteros, J. A. & Weinstein, H. In Methods in Neurosciences (Sealfon, S. C. ed.), Vol. 25, 366\u2013428 (Academic Press, 1995).","DOI":"10.1016\/S1043-9471(05)80049-7"},{"key":"62872_CR47","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.tips.2014.11.001","volume":"36","author":"V Isberg","year":"2015","unstructured":"Isberg, V. et al. Generic GPCR residue numbers\u2014aligning topology maps while minding the gaps. Trends Pharm. Sci. 36, 22\u201331 (2015).","journal-title":"Trends Pharm. Sci."},{"key":"62872_CR48","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1016\/S0028-3908(97)00104-4","volume":"36","author":"KA Jacobson","year":"1997","unstructured":"Jacobson, K. A. et al. Pharmacological characterization of novel A3 adenosine receptor-selective antagonists. Neuropharmacology 36, 1157\u20131165 (1997).","journal-title":"Neuropharmacology"},{"key":"62872_CR49","doi-asserted-by":"publisher","first-page":"3337","DOI":"10.1021\/jm0208469","volume":"45","author":"EM Priego","year":"2002","unstructured":"Priego, E. M., von Frijtag Drabbe Kuenzel, J., AP, I. J., Camarasa, M. J. & P\u00e9rez-P\u00e9rez, M. J. Pyrido[2,1-f]purine-2,4-dione derivatives as a novel class of highly potent human A(3) adenosine receptor antagonists. J. Med. Chem. 45, 3337\u20133344 (2002).","journal-title":"J. Med. Chem."},{"key":"62872_CR50","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/S0026-895X(25)09142-4","volume":"50","author":"M Srinivas","year":"1996","unstructured":"Srinivas, M. et al. A novel irreversible antagonist of the A1-adenosine receptor. Mol. Pharm. 50, 196\u2013205 (1996).","journal-title":"Mol. Pharm."},{"key":"62872_CR51","doi-asserted-by":"publisher","first-page":"6670","DOI":"10.1021\/acs.jmedchem.0c02067","volume":"64","author":"E Comeo","year":"2021","unstructured":"Comeo, E. et al. Development and application of subtype-selective fluorescent antagonists for the study of the human adenosine A(1) receptor in living cells. J. Med. Chem. 64, 6670\u20136695 (2021).","journal-title":"J. Med. Chem."},{"key":"62872_CR52","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.neuropharm.2015.04.033","volume":"98","author":"LA Stoddart","year":"2015","unstructured":"Stoddart, L. A., Kilpatrick, L. E., Briddon, S. J. & Hill, S. J. Probing the pharmacology of G protein-coupled receptors with fluorescent ligands. Neuropharmacology 98, 48\u201357 (2015).","journal-title":"Neuropharmacology"},{"key":"62872_CR53","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1016\/j.chembiol.2012.07.014","volume":"19","author":"LA Stoddart","year":"2012","unstructured":"Stoddart, L. A. et al. Fragment screening at adenosine-A(3) receptors in living cells using a fluorescence-based binding assay. Chem. Biol. 19, 1105\u20131115 (2012).","journal-title":"Chem. Biol."},{"key":"62872_CR54","doi-asserted-by":"publisher","first-page":"8161","DOI":"10.1021\/acs.jmedchem.0c02169","volume":"64","author":"PNH Trinh","year":"2021","unstructured":"Trinh, P. N. H. et al. Development of covalent, clickable probes for adenosine A(1) and A(3) receptors. J. Med. Chem. 64, 8161\u20138178 (2021).","journal-title":"J. Med. Chem."},{"key":"62872_CR55","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/j.str.2011.06.014","volume":"19","author":"AS Dor\u00e9","year":"2011","unstructured":"Dor\u00e9, A. S. et al. Structure of the adenosine A(2A) receptor in complex with ZM241385 and the xanthines XAC and caffeine. Structure 19, 1283\u20131293 (2011).","journal-title":"Structure"},{"key":"62872_CR56","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1124\/molpharm.122.000633","volume":"103","author":"Y Ohno","year":"2023","unstructured":"Ohno, Y. et al. In vitro pharmacological profile of KW-6356, a novel adenosine A(2A) receptor antagonist\/inverse agonist. Mol. Pharm. 103, 311\u2013324 (2023).","journal-title":"Mol. Pharm."},{"key":"62872_CR57","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1124\/mol.115.102657","volume":"89","author":"D Guo","year":"2016","unstructured":"Guo, D. et al. Molecular basis of ligand dissociation from the adenosine A2A receptor. Mol. Pharm. 89, 485\u2013491 (2016).","journal-title":"Mol. Pharm."},{"key":"62872_CR58","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1016\/j.bcp.2013.03.005","volume":"85","author":"BF Seibt","year":"2013","unstructured":"Seibt, B. F. et al. The second extracellular loop of GPCRs determines subtype-selectivity and controls efficacy as evidenced by loop exchange study at A2 adenosine receptors. Biochem Pharm. 85, 1317\u20131329 (2013).","journal-title":"Biochem Pharm."},{"key":"62872_CR59","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.tips.2010.10.001","volume":"32","author":"MC Peeters","year":"2011","unstructured":"Peeters, M. C., van Westen, G. J., Li, Q. & IJzerman, A. P. Importance of the extracellular loops in G protein-coupled receptors for ligand recognition and receptor activation. Trends Pharm. Sci. 32, 35\u201342 (2011).","journal-title":"Trends Pharm. Sci."},{"key":"62872_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2019.113718","volume":"172","author":"E De Filippo","year":"2020","unstructured":"De Filippo, E. et al. A(2A) and A(2B) adenosine receptors: the extracellular loop 2 determines high (A(2A)) or low affinity (A(2B)) for adenosine. Biochem Pharm. 172, 113718 (2020).","journal-title":"Biochem Pharm."},{"key":"62872_CR61","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1124\/mol.116.105007","volume":"90","author":"AT Nguyen","year":"2016","unstructured":"Nguyen, A. T. et al. Extracellular loop 2 of the adenosine A1 receptor has a key role in orthosteric ligand affinity and agonist efficacy. Mol. Pharm. 90, 703\u2013714 (2016).","journal-title":"Mol. Pharm."},{"key":"62872_CR62","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1124\/mol.114.097360","volume":"87","author":"G Lebon","year":"2015","unstructured":"Lebon, G., Edwards, P. C., Leslie, A. G. & Tate, C. G. Molecular determinants of CGS21680 binding to the human adenosine A2A receptor. Mol. Pharm. 87, 907\u2013915 (2015).","journal-title":"Mol. Pharm."},{"key":"62872_CR63","doi-asserted-by":"publisher","first-page":"13118","DOI":"10.1073\/pnas.1104614108","volume":"108","author":"RO Dror","year":"2011","unstructured":"Dror, R. O. et al. Pathway and mechanism of drug binding to G-protein-coupled receptors. Proc. Natl. Acad. Sci. USA 108, 13118\u201313123 (2011).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"62872_CR64","doi-asserted-by":"publisher","first-page":"19056","DOI":"10.1074\/jbc.M110960200","volume":"277","author":"ZG Gao","year":"2002","unstructured":"Gao, Z. G. et al. Identification by site-directed mutagenesis of residues involved in ligand recognition and activation of the human A3 adenosine receptor. J. Biol. Chem. 277, 19056\u201319063 (2002).","journal-title":"J. Biol. Chem."},{"key":"62872_CR65","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-06002-w","volume":"9","author":"S Maeda","year":"2018","unstructured":"Maeda, S. et al. Development of an antibody fragment that stabilizes GPCR\/G-protein complexes. Nat. Commun. 9, 3712 (2018).","journal-title":"Nat. Commun."},{"key":"62872_CR66","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/s41586-018-0535-y","volume":"561","author":"YL Liang","year":"2018","unstructured":"Liang, Y. L. et al. Cryo-EM structure of the active, G(s)-protein complexed, human CGRP receptor. Nature 561, 492\u2013497 (2018).","journal-title":"Nature"},{"key":"62872_CR67","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1021\/acsptsci.8b00017","volume":"1","author":"YL Liang","year":"2018","unstructured":"Liang, Y. L. et al. Dominant negative G proteins enhance formation and purification of agonist-GPCR-G protein complexes for structure determination. ACS Pharm. Transl. Sci. 1, 12\u201320 (2018).","journal-title":"ACS Pharm. Transl. Sci."},{"key":"62872_CR68","doi-asserted-by":"publisher","first-page":"e0175642","DOI":"10.1371\/journal.pone.0175642","volume":"12","author":"R Nehm\u00e9","year":"2017","unstructured":"Nehm\u00e9, R. et al. Mini-G proteins: novel tools for studying GPCRs in their active conformation. PLoS One 12, e0175642 (2017).","journal-title":"PLoS One"},{"key":"62872_CR69","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/nature10361","volume":"477","author":"SG Rasmussen","year":"2011","unstructured":"Rasmussen, S. G. et al. Crystal structure of the \u03b22 adrenergic receptor-Gs protein complex. Nature 477, 549\u2013555 (2011).","journal-title":"Nature"},{"key":"62872_CR70","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1358\/dof.1995.020.07.531583","volume":"20","author":"KA Jacobson","year":"1995","unstructured":"Jacobson, K. A. et al. A(3)-adenosine receptors: design of selective ligands and therapeutic prospects. Drugs Future 20, 689\u2013699 (1995).","journal-title":"Drugs Future"},{"key":"62872_CR71","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1016\/S0026-895X(25)10559-2","volume":"45","author":"PJ van Galen","year":"1994","unstructured":"van Galen, P. J. et al. A binding site model and structure-activity relationships for the rat A3 adenosine receptor. Mol. Pharm. 45, 1101\u20131111 (1994).","journal-title":"Mol. Pharm."},{"key":"62872_CR72","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1124\/mol.63.5.1021","volume":"63","author":"ZG Gao","year":"2003","unstructured":"Gao, Z. G. et al. Identification of essential residues involved in the allosteric modulation of the human A(3) adenosine receptor. Mol. Pharm. 63, 1021\u20131031 (2003).","journal-title":"Mol. Pharm."},{"key":"62872_CR73","doi-asserted-by":"publisher","first-page":"3136","DOI":"10.1021\/acs.jcim.9b00128","volume":"59","author":"Y Wang","year":"2019","unstructured":"Wang, Y., Fu, Q., Zhou, Y., Du, Y. & Huang, N. Replacement of protein binding-site waters contributes to favorable halogen bond interactions. J. Chem. Inf. Model 59, 3136\u20133143 (2019).","journal-title":"J. Chem. Inf. Model"},{"key":"62872_CR74","doi-asserted-by":"publisher","first-page":"8831","DOI":"10.1021\/acs.jmedchem.9b01164","volume":"62","author":"D Stamatis","year":"2019","unstructured":"Stamatis, D. et al. Structural characterization of agonist binding to an A(3) adenosine receptor through biomolecular simulations and mutagenesis experiments. J. Med. Chem. 62, 8831\u20138846 (2019).","journal-title":"J. Med. Chem."},{"key":"62872_CR75","doi-asserted-by":"publisher","first-page":"11308","DOI":"10.1073\/pnas.1206710110","volume":"110","author":"JP Schwans","year":"2013","unstructured":"Schwans, J. P. et al. Use of anion-aromatic interactions to position the general base in the ketosteroid isomerase active site. Proc. Natl. Acad. Sci. USA 110, 11308\u201311313 (2013).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"62872_CR76","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.tips.2009.02.006","volume":"30","author":"R Nygaard","year":"2009","unstructured":"Nygaard, R., Frimurer, T. M., Holst, B., Rosenkilde, M. M. & Schwartz, T. W. Ligand binding and micro-switches in 7TM receptor structures. Trends Pharm. Sci. 30, 249\u2013259 (2009).","journal-title":"Trends Pharm. Sci."},{"key":"62872_CR77","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1021\/acsptsci.8b00026","volume":"1","author":"A Glukhova","year":"2018","unstructured":"Glukhova, A. et al. Rules of engagement: GPCRs and G proteins. ACS Pharm. Transl. Sci. 1, 73\u201383 (2018).","journal-title":"ACS Pharm. Transl. Sci."},{"key":"62872_CR78","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1038\/s41589-020-0535-8","volume":"16","author":"RHJ Olsen","year":"2020","unstructured":"Olsen, R. H. J. et al. TRUPATH, an open-source biosensor platform for interrogating the GPCR transducerome. Nat. Chem. Biol. 16, 841\u2013849 (2020).","journal-title":"Nat. Chem. Biol."},{"key":"62872_CR79","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1098\/rspb.1983.0093","volume":"220","author":"JW Black","year":"1983","unstructured":"Black, J. W. & Leff, P. Operational models of pharmacological agonism. Proc. R. Soc. Lond. B Biol. Sci. 220, 141\u2013162 (1983).","journal-title":"Proc. R. Soc. Lond. B Biol. Sci."},{"key":"62872_CR80","doi-asserted-by":"publisher","first-page":"7459","DOI":"10.1074\/jbc.M109.094011","volume":"285","author":"KJ Gregory","year":"2010","unstructured":"Gregory, K. J., Hall, N. E., Tobin, A. B., Sexton, P. M. & Christopoulos, A. Identification of orthosteric and allosteric site mutations in M2 muscarinic acetylcholine receptors that contribute to ligand-selective signaling bias. J. Biol. Chem. 285, 7459\u20137474 (2010).","journal-title":"J. Biol. Chem."},{"key":"62872_CR81","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/nrd3955","volume":"12","author":"JF Chen","year":"2013","unstructured":"Chen, J. F., Eltzschig, H. K. & Fredholm, B. B. Adenosine receptors as drug targets\u2013what are the challenges?. Nat. Rev. Drug Discov. 12, 265\u2013286 (2013).","journal-title":"Nat. Rev. Drug Discov."},{"key":"62872_CR82","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17933-8","volume":"11","author":"J Duan","year":"2020","unstructured":"Duan, J. et al. Cryo-EM structure of an activated VIP1 receptor-G protein complex revealed by a NanoBiT tethering strategy. Nat. Commun. 11, 4121 (2020).","journal-title":"Nat. Commun."},{"key":"62872_CR83","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1016\/j.bbamem.2010.12.017","volume":"1808","author":"CE M\u00fcller","year":"2011","unstructured":"M\u00fcller, C. E. & Jacobson, K. A. Recent developments in adenosine receptor ligands and their potential as novel drugs. Biochim Biophys. Acta 1808, 1290\u20131308 (2011).","journal-title":"Biochim Biophys. Acta"},{"key":"62872_CR84","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2023.109503","volume":"230","author":"KA Jacobson","year":"2023","unstructured":"Jacobson, K. A., Pradhan, B., Wen, Z. & Pramanik, A. New paradigms in purinergic receptor ligand discovery. Neuropharmacology 230, 109503 (2023).","journal-title":"Neuropharmacology"},{"key":"62872_CR85","doi-asserted-by":"publisher","unstructured":"Jacobson, K. A. et al. Medicinal chemistry of the A3 adenosine receptor: agonists, antagonists, and receptor engineering. Handb Exp Pharmacol. https:\/\/doi.org\/10.1007\/978-3-540-89615-9_5 (2009).","DOI":"10.1007\/978-3-540-89615-9_5"},{"key":"62872_CR86","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1002\/med.21456","volume":"38","author":"KA Jacobson","year":"2018","unstructured":"Jacobson, K. A. et al. A(3) Adenosine receptors as modulators of inflammation: from medicinal chemistry to therapy. Med Res. Rev. 38, 1031\u20131072 (2018).","journal-title":"Med Res. Rev."},{"key":"62872_CR87","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1007\/BF00165806","volume":"336","author":"MJ Lohse","year":"1987","unstructured":"Lohse, M. J. et al. 8-Cyclopentyl-1,3-dipropylxanthine (DPCPX)\u2013a selective high affinity antagonist radioligand for A1 adenosine receptors. Naunyn Schmiedebergs Arch. Pharmacol. 336, 204\u2013210 (1987).","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"62872_CR88","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1038\/s41594-022-00859-8","volume":"29","author":"MJ Robertson","year":"2022","unstructured":"Robertson, M. J. et al. Structure determination of inactive-state GPCRs with a universal nanobody. Nat. Struct. Mol. Biol. 29, 1188\u20131195 (2022).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"62872_CR89","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41589-023-01389-0","volume":"20","author":"Q Guo","year":"2024","unstructured":"Guo, Q. et al. A method for structure determination of GPCRs in various states. Nat. Chem. Biol. 20, 74\u201382 (2024).","journal-title":"Nat. Chem. Biol."},{"key":"62872_CR90","doi-asserted-by":"publisher","first-page":"4847","DOI":"10.1021\/jm300396n","volume":"55","author":"DK Tosh","year":"2012","unstructured":"Tosh, D. K. et al. Structure-guided design of A(3) adenosine receptor-selective nucleosides: combination of 2-arylethynyl and bicyclo[3.1.0]hexane substitutions. J. Med. Chem. 55, 4847\u20134860 (2012).","journal-title":"J. Med. Chem."},{"key":"62872_CR91","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1124\/mol.116.103283","volume":"90","author":"JA Baltos","year":"2016","unstructured":"Baltos, J. A. et al. Structure-activity analysis of biased agonism at the human adenosine A3 receptor. Mol. Pharm. 90, 12\u201322 (2016).","journal-title":"Mol. Pharm."},{"key":"62872_CR92","doi-asserted-by":"publisher","first-page":"3614","DOI":"10.1021\/jm00047a018","volume":"37","author":"HO Kim","year":"1994","unstructured":"Kim, H. O. et al. 2-Substitution of N6-benzyladenosine-5\u2019-uronamides enhances selectivity for A3 adenosine receptors. J. Med. Chem. 37, 3614\u20133621 (1994).","journal-title":"J. Med. Chem."},{"key":"62872_CR93","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.jmb.2016.01.029","volume":"428","author":"P Cimermancic","year":"2016","unstructured":"Cimermancic, P. et al. CryptoSite: expanding the druggable proteome by characterization and prediction of cryptic binding sites. J. Mol. Biol. 428, 709\u2013719 (2016).","journal-title":"J. Mol. Biol."},{"key":"62872_CR94","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cbpa.2018.05.003","volume":"44","author":"S Vajda","year":"2018","unstructured":"Vajda, S., Beglov, D., Wakefield, A. E., Egbert, M. & Whitty, A. Cryptic binding sites on proteins: definition, detection, and druggability. Curr. Opin. Chem. Biol. 44, 1\u20138 (2018).","journal-title":"Curr. Opin. Chem. Biol."},{"key":"62872_CR95","doi-asserted-by":"publisher","first-page":"8131","DOI":"10.1073\/pnas.1814131116","volume":"116","author":"BC Taylor","year":"2019","unstructured":"Taylor, B. C., Lee, C. T. & Amaro, R. E. Structural basis for ligand modulation of the CCR2 conformational landscape. Proc. Natl. Acad. Sci. USA 116, 8131\u20138136 (2019).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"62872_CR96","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-11062-7","volume":"10","author":"SA Hollingsworth","year":"2019","unstructured":"Hollingsworth, S. A. et al. Cryptic pocket formation underlies allosteric modulator selectivity at muscarinic GPCRs. Nat. Commun. 10, 3289 (2019).","journal-title":"Nat. Commun."},{"key":"62872_CR97","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-19345-7","volume":"8","author":"N Ferruz","year":"2018","unstructured":"Ferruz, N. et al. Dopamine D3 receptor antagonist reveals a cryptic pocket in aminergic GPCRs. Sci. Rep. 8, 897 (2018).","journal-title":"Sci. Rep."},{"key":"62872_CR98","doi-asserted-by":"publisher","first-page":"10982","DOI":"10.1073\/pnas.1309755110","volume":"110","author":"Y Miao","year":"2013","unstructured":"Miao, Y., Nichols, S. E., Gasper, P. M., Metzger, V. T. & McCammon, J. A. Activation and dynamic network of the M2 muscarinic receptor. Proc. Natl. Acad. Sci. USA 110, 10982\u201310987 (2013).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"62872_CR99","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2203702119","volume":"119","author":"Y Li","year":"2022","unstructured":"Li, Y., Sun, J., Li, D. & Lin, J. The full activation mechanism of the adenosine A(1) receptor revealed by GaMD and Su-GaMD simulations. Proc. Natl. Acad. Sci. USA 119, e2203702119 (2022).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"62872_CR100","doi-asserted-by":"crossref","unstructured":"Maria-Solano, M. A. & Choi, S. Dynamic allosteric networks drive adenosine A(1) receptor activation and G-protein coupling. Elife 12, RP90773 (2023).","DOI":"10.7554\/eLife.90773"},{"key":"62872_CR101","doi-asserted-by":"publisher","first-page":"18684","DOI":"10.1073\/pnas.1110499108","volume":"108","author":"RO Dror","year":"2011","unstructured":"Dror, R. O. et al. Activation mechanism of the \u03b22-adrenergic receptor. Proc. Natl. Acad. Sci. USA 108, 18684\u201318689 (2011).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"62872_CR102","doi-asserted-by":"crossref","unstructured":"Vuckovic, Z. et al. Pharmacological hallmarks of allostery at the M4 muscarinic receptor elucidated through structure and dynamics. Elife 12, e83477 (2023).","DOI":"10.7554\/eLife.83477"},{"key":"62872_CR103","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1038\/s41589-018-0145-x","volume":"14","author":"M Masureel","year":"2018","unstructured":"Masureel, M. et al. Structural insights into binding specificity, efficacy and bias of a \u03b2(2)AR partial agonist. Nat. Chem. Biol. 14, 1059\u20131066 (2018).","journal-title":"Nat. Chem. Biol."},{"key":"62872_CR104","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.cell.2020.03.003","volume":"181","author":"M Congreve","year":"2020","unstructured":"Congreve, M., de Graaf, C., Swain, N. A. & Tate, C. G. Impact of GPCR Structures on Drug Discovery. Cell 181, 81\u201391 (2020).","journal-title":"Cell"},{"key":"62872_CR105","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.phrs.2008.02.008","volume":"57","author":"ZG Gao","year":"2008","unstructured":"Gao, Z. G. & Jacobson, K. A. Translocation of arrestin induced by human A(3) adenosine receptor ligands in an engineered cell line: comparison with G protein-dependent pathways. Pharm. Res. 57, 303\u2013311 (2008).","journal-title":"Pharm. Res."},{"key":"62872_CR106","doi-asserted-by":"publisher","first-page":"4614","DOI":"10.1073\/pnas.1320962111","volume":"111","author":"C Valant","year":"2014","unstructured":"Valant, C. et al. Separation of on-target efficacy from adverse effects through rational design of a bitopic adenosine receptor agonist. Proc. Natl. Acad. Sci. USA 111, 4614\u20134619 (2014).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"62872_CR107","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.bcp.2015.11.013","volume":"99","author":"JA Baltos","year":"2016","unstructured":"Baltos, J. A. et al. Quantification of adenosine A(1) receptor biased agonism: implications for drug discovery. Biochem. Pharm. 99, 101\u2013112 (2016).","journal-title":"Biochem. Pharm."},{"key":"62872_CR108","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/j.bcp.2011.06.017","volume":"82","author":"ZG Gao","year":"2011","unstructured":"Gao, Z. G. et al. Functionally biased modulation of A(3) adenosine receptor agonist efficacy and potency by imidazoquinolinamine allosteric enhancers. Biochem. Pharm. 82, 658\u2013668 (2011).","journal-title":"Biochem. Pharm."},{"key":"62872_CR109","doi-asserted-by":"publisher","first-page":"4036","DOI":"10.1111\/bph.14337","volume":"175","author":"EA Vecchio","year":"2018","unstructured":"Vecchio, E. A. et al. New paradigms in adenosine receptor pharmacology: allostery, oligomerization and biased agonism. Br. J. Pharm. 175, 4036\u20134046 (2018).","journal-title":"Br. J. Pharm."},{"key":"62872_CR110","doi-asserted-by":"crossref","unstructured":"Garc\u00eda-Nafr\u00eda, J., Lee, Y., Bai, X., Carpenter, B. & Tate, C. G. Cryo-EM structure of the adenosine A(2A) receptor coupled to an engineered heterotrimeric G protein. Elife 7, e35946 (2018).","DOI":"10.7554\/eLife.35946"},{"key":"62872_CR111","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/s41589-021-00890-8","volume":"18","author":"JA Harris","year":"2022","unstructured":"Harris, J. A. et al. Selective G protein signaling driven by substance P-neurokinin receptor dynamics. Nat. Chem. Biol. 18, 109\u2013115 (2022).","journal-title":"Nat. Chem. Biol."},{"key":"62872_CR112","doi-asserted-by":"publisher","first-page":"e3001295","DOI":"10.1371\/journal.pbio.3001295","volume":"19","author":"JI Mobbs","year":"2021","unstructured":"Mobbs, J. I. et al. Structures of the human cholecystokinin 1 (CCK1) receptor bound to Gs and Gq mimetic proteins provide insight into mechanisms of G protein selectivity. PLoS Biol. 19, e3001295 (2021).","journal-title":"PLoS Biol."},{"key":"62872_CR113","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.tips.2017.11.001","volume":"39","author":"W Jespers","year":"2018","unstructured":"Jespers, W. et al. Structural mapping of adenosine receptor mutations: ligand binding and signaling mechanisms. Trends Pharm. Sci. 39, 75\u201389 (2018).","journal-title":"Trends Pharm. Sci."},{"key":"62872_CR114","doi-asserted-by":"crossref","unstructured":"Ciancetta, A., Jacobson, K. A. Structural probing and molecular modeling of the A3 adenosine receptor: a focus on agonist binding. Molecules 22, 449 (2017).","DOI":"10.3390\/molecules22030449"},{"key":"62872_CR115","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.jmb.2017.12.010","volume":"430","author":"J Ere\u00f1o-Orbea","year":"2018","unstructured":"Ere\u00f1o-Orbea, J. et al. Structural basis of enhanced crystallizability induced by a molecular chaperone for antibody antigen-binding fragments. J. Mol. Biol. 430, 322\u2013336 (2018).","journal-title":"J. Mol. Biol."},{"key":"62872_CR116","doi-asserted-by":"publisher","first-page":"e0210131","DOI":"10.1371\/journal.pone.0210131","volume":"14","author":"A Kumar","year":"2019","unstructured":"Kumar, A. & Pl\u00fcckthun, A. In vivo assembly and large-scale purification of a GPCR\u2013G\u03b1 fusion with G\u03b2\u03b3, and characterization of the active complex. PLoS One 14, e0210131 (2019).","journal-title":"PLoS One"},{"key":"62872_CR117","doi-asserted-by":"publisher","first-page":"3028","DOI":"10.1111\/bph.13316","volume":"173","author":"LA Stoddart","year":"2016","unstructured":"Stoddart, L. A., White, C. W., Nguyen, K., Hill, S. J. & Pfleger, K. D. Fluorescence- and bioluminescence-based approaches to study GPCR ligand binding. Br. J. Pharm. 173, 3028\u20133037 (2016).","journal-title":"Br. J. Pharm."},{"key":"62872_CR118","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/nmeth.4193","volume":"14","author":"SQ Zheng","year":"2017","unstructured":"Zheng, S. Q. et al. MotionCor2: anisotropic correction of beam-induced motion for improved cryo-electron microscopy. Nat. Methods 14, 331\u2013332 (2017).","journal-title":"Nat. Methods"},{"key":"62872_CR119","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jsb.2015.11.003","volume":"193","author":"K Zhang","year":"2016","unstructured":"Zhang, K. Gctf: Real-time CTF determination and correction. J. Struct. Biol. 193, 1\u201312 (2016).","journal-title":"J. Struct. Biol."},{"key":"62872_CR120","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/nmeth.4169","volume":"14","author":"A Punjani","year":"2017","unstructured":"Punjani, A., Rubinstein, J. L., Fleet, D. J. & Brubaker, M. A. cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination. Nat. Methods 14, 290\u2013296 (2017).","journal-title":"Nat. Methods"},{"key":"62872_CR121","doi-asserted-by":"crossref","unstructured":"J. Zivanov et al. New tools for automated high-resolution cryo-EM structure determination in RELION-3. Elife 7, e42166 (2018).","DOI":"10.7554\/eLife.42166"},{"key":"62872_CR122","doi-asserted-by":"publisher","first-page":"D313","DOI":"10.1093\/nar\/gkw1132","volume":"45","author":"S Bienert","year":"2017","unstructured":"Bienert, S. et al. The SWISS-MODEL repository-new features and functionality. Nucleic Acids Res. 45, D313\u2013d319 (2017).","journal-title":"Nucleic Acids Res."},{"key":"62872_CR123","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/j.molcel.2021.01.003","volume":"81","author":"P Xu","year":"2021","unstructured":"Xu, P. et al. Structures of the human dopamine D3 receptor-G(i) complexes. Mol. Cell 81, 1147\u20131159.e1144 (2021).","journal-title":"Mol. Cell"},{"key":"62872_CR124","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1002\/jcc.20084","volume":"25","author":"EF Pettersen","year":"2004","unstructured":"Pettersen, E. F. et al. UCSF Chimera\u2014a visualization system for exploratory research and analysis. J. Comput. Chem. 25, 1605\u20131612 (2004).","journal-title":"J. Comput. Chem."},{"key":"62872_CR125","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1107\/S0907444909052925","volume":"66","author":"PD Adams","year":"2010","unstructured":"Adams, P. D. et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D. Biol. Crystallogr. 66, 213\u2013221 (2010).","journal-title":"Acta Crystallogr. D. Biol. Crystallogr."},{"key":"62872_CR126","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1107\/S0907444910007493","volume":"66","author":"P Emsley","year":"2010","unstructured":"Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot. Acta Crystallogr D. Biol. Crystallogr 66, 486\u2013501 (2010).","journal-title":"Acta Crystallogr D. Biol. Crystallogr"},{"key":"62872_CR127","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1038\/s41586-022-04580-w","volume":"604","author":"X Qu","year":"2022","unstructured":"Qu, X. et al. Structural basis of tethered agonism of the adhesion GPCRs ADGRD1 and ADGRF1. Nature 604, 779\u2013785 (2022).","journal-title":"Nature"},{"key":"62872_CR128","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1038\/s42003-021-02399-1","volume":"4","author":"R Sanchez-Garcia","year":"2021","unstructured":"Sanchez-Garcia, R. et al. DeepEMhancer: a deep learning solution for cryo-EM volume post-processing. Commun. Biol. 4, 874 (2021).","journal-title":"Commun. Biol."},{"key":"62872_CR129","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1002\/pro.3330","volume":"27","author":"CJ Williams","year":"2018","unstructured":"Williams, C. J. et al. MolProbity: more and better reference data for improved all-atom structure validation. Protein Sci. 27, 293\u2013315 (2018).","journal-title":"Protein Sci."},{"key":"62872_CR130","doi-asserted-by":"publisher","DOI":"10.1002\/pro.4792","volume":"32","author":"EC Meng","year":"2023","unstructured":"Meng, E. C. et al. UCSF ChimeraX: tools for structure building and analysis. Protein Sci. 32, e4792 (2023).","journal-title":"Protein Sci."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-62872-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-62872-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-62872-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T05:54:50Z","timestamp":1757397290000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-62872-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,18]]},"references-count":130,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["62872"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-62872-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2025.01.12.632629","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,18]]},"assertion":[{"value":"17 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.C. is a co-founder and shareholder of Septerna Inc. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7674"}}